KRAS and lung adenocarcinoma: In order to better understand potential racial and ethnic differences in response to PCAIs treatments, future work will also employ a range of lung adenocarcinoma cell lines with unique KRAS mutations especially from Blacks to determine whether the responses to PCAIs vary with different KRAS mutations.